Publications by authors named "Danielle Curcio"

Claim this Profile
E
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.
Michael H Davidson, Michael Szarek, Philip Scheltens, Everard Vijverberg, Andrew Hsieh, Danielle Curcio

J Prev Alzheimers Dis· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, John J P Kastelein, Christie M Ballantyne, Danielle L Curcio

N Engl J Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials.
Stephen J Nicholls, Adam J Nelson, John J P Kastelein, Marc Ditmarsch, Andrew Hsieh, Danielle Curcio

Pharmacol Res Perspect· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, John J P Kastelein, Christie M Ballantyne, Danielle Curcio

Am Heart J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
Christie M Ballantyne, Marc Ditmarsch, John Jp Kastelein, Adam J Nelson, Douglas Kling, Danielle L Curcio

J Clin Lipidol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
Stephen J Nicholls, Marc Ditmarsch, John J Kastelein, Scott P Rigby, Douglas Kling, Danielle L Curcio

Nat Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, Danielle Curcio

N Engl J Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Richard L Dunbar, Stephen J Nicholls, Kevin C Maki, Eli M Roth, David G Orloff, Danielle Curcio

Lipids Health Dis· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Elliot Offman, Ted Marenco, Sandy Ferber, Judith Johnson, Douglas Kling, Danielle Curcio

Vasc Health Risk Manag· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Kevin C Maki, David G Orloff, Stephen J Nicholls, Richard L Dunbar, Eli M Roth, Danielle Curcio

Clin Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis